» Articles » PMID: 28039162

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma

Overview
Date 2017 Jan 1
PMID 28039162
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Tumors expressing programmed death ligand 1 (PD-L1) interact with the corresponding negative-signal generating immune receptor on the surface of CD8 T cells, PD-1, thereby suppressing antitumor activity. Therapeutics blocking this interaction have shown promise in various cancers by restoring functional antitumor T-cell activity. We explored the degree of PD-L1, PD-1, and CD8 expression in a retrospective analysis of 29 clinical synovial sarcoma samples. Quantitative immunohistochemistry and multiplex immunofluorescence were used to determine relative quantification of CD8 and PD-1 T cells and PD-L1 expression within the intratumor area and the interface between the tumor and the surrounding nontumor tissue (i.e., invasive margin), and colocalization of these factors, respectively. PD-L1, PD-1, and CD8 cell densities in the tumor-invasive margins were significantly higher in the metastatic tumors than the primary tumors (P < 0.01), and PD-L1, PD-1, and CD8 cell densities were all significantly positively correlated with one other (P < 0.0001). PD-1 cell density in the tumor-invasive margin was significantly associated with worse progression-free survival. Multiplex immunofluorescence demonstrated coexpression of PD-1 and CD8 on lymphocytes within the invasive margin, as well as relative proximity between PD-1 CD8 cells and PD-L1 tumor cells. Our results provide a preclinical rationale for screening of patients with synovial sarcoma for the colocalization of CD8, PD-1, and PD-L1, which may be a marker for response to PD-1 blockade therapy. Cancer Immunol Res; 5(2); 118-26. ©2016 AACR.

Citing Articles

PD‑1/PD‑L1 immune checkpoint in bone and soft tissue tumors (Review).

Hashimoto K, Nishimura S, Goto K Mol Clin Oncol. 2025; 22(4):31.

PMID: 39989606 PMC: 11843085. DOI: 10.3892/mco.2025.2826.


Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer.

Qu F, Wu S, Yu W Onco Targets Ther. 2024; 17:1223-1253.

PMID: 39735789 PMC: 11681808. DOI: 10.2147/OTT.S500281.


Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy.

Luk S, IJsselsteijn M, Somarakis A, Acem I, de Bruijn I, Szuhai K Cancer Immunol Immunother. 2024; 74(1):31.

PMID: 39708175 PMC: 11663204. DOI: 10.1007/s00262-024-03868-2.


Primary cardiac synovial sarcoma originating from the atrial septum and associated pulmonary infarction: a case report.

Xu N, Xie K, Xin D, Liang Z, Zeng Y J Cancer Res Clin Oncol. 2024; 150(8):392.

PMID: 39162837 PMC: 11335867. DOI: 10.1007/s00432-024-05852-w.


Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer.

Haq A, Yang P, Jin C, Shih J, Chen L, Tseng H Theranostics. 2024; 14(5):2167-2189.

PMID: 38505617 PMC: 10945351. DOI: 10.7150/thno.92922.


References
1.
Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P . Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014; 4(6):674-87. DOI: 10.1158/2159-8290.CD-13-0458. View

2.
Muenst S, Soysal S, Gao F, Obermann E, Oertli D, Gillanders W . The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013; 139(3):667-76. PMC: 3885332. DOI: 10.1007/s10549-013-2581-3. View

3.
Fife B, Pauken K, Eagar T, Obu T, Wu J, Tang Q . Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009; 10(11):1185-92. PMC: 2778301. DOI: 10.1038/ni.1790. View

4.
Darb-Esfahani S, Kunze C, Kulbe H, Sehouli J, Wienert S, Lindner J . Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2015; 7(2):1486-99. PMC: 4811475. DOI: 10.18632/oncotarget.6429. View

5.
Thway K, Fisher C . Synovial sarcoma: defining features and diagnostic evolution. Ann Diagn Pathol. 2014; 18(6):369-80. DOI: 10.1016/j.anndiagpath.2014.09.002. View